Ying Huang, Martin Sendzik, Jeff Zhang, Zhenting Gao, Yongfeng Sun, Long Wang, Justin Gu, Kehao Zhao, Zhengtian Yu, Lijun Zhang, Qiong Zhang, Joachim Blanz, Zijun Chen, Valerie Dubost, Douglas Fang, Lijian Feng, Xingnian Fu, Michael Kiffe, Ling Li, Fangjun Luo, Xiao Luo, Yuan Mi, Prakash Mistry, David Pearson, Alessandro Piaia, Clemens Scheufler, Remi Terranova, Andreas Weiss, Jue Zeng, Hailong Zhang, Jiangwei Zhang, Mengxi Zhao, Michael P. Dillon, Sebastien Jeay, Wei Qi, Jonathan Moggs, Carole Pissot-Soldermann, En Li, Peter Atadja, Andreas Lingel, Counde Oyang, Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. Journal of Medicinal Chemistry, 65, 5317-5333(2022e).
https://doi.org/10.1021/acs.jmedchem.1c02148